4-amino-1-((3-chlorophenyl)sulfonyl)piperidine-4-carbonitrile | 1253923-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-1-((3-chlorophenyl)sulfonyl)piperidine-4-carbonitrile
• 英文别名: 4-amino-1-(3-chloro-benzenesulfonyl)-piperidine-4-carbonitrile；4-Amino-1-(3-chloro-benzenesulfonyl)-piperidine-4-carbonitrile；4-amino-1-(3-chlorophenyl)sulfonylpiperidine-4-carbonitrile
• CAS: 1253923-88-4
• 化学式: C₁₂H₁₄ClN₃O₂S
• 分子量: 299.781
• InChiKey: WIHRQHOYVXTBQC-UHFFFAOYSA-N

物化性质

• 沸点：
  501.0±60.0 °C(Predicted)
• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  95.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-amino-1-((3-chlorophenyl)sulfonyl)piperidine-4-carbonitrile 在 双氧水 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 14.0h， 生成 2-(4-chlorophenyl)-8-((3-chlorophenyl)sulfonyl)-1,3,8-triazaspiro[4.5]dec-1-en-4-one
  参考文献：
  名称：

  Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

  摘要：

  During the course of derivatization of HTS hit 4a, we have identified a novel small-molecule hPTHRl agonist, l-(3,5-dimethyl-4-(2-((2-((lR,4R)-4-methylcyclohexyl)-4-oxo-l,3,8-triazaspiro[4.5]dec-l-en-8-yl)sulfonyl)ethyl)-phenyl)-l-methylurea (CH5447240, 141). Compound 141 exhibited a potent in vitro hPTHRl agonist effect with EC20 of 3.0 mu M and EC50 of 12 mu M and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes. Importantly, 141 showed 55% oral bioavailability and a significantly elevated serum calcium level in hypocalcemic model rats.

  DOI：

  10.1021/acs.jmedchem.8b00182
• 作为产物：
  描述：

  4-氧代哌啶酮盐酸盐 在 ammonium acetate 、 potassium carbonate 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 反应 17.0h， 生成 4-amino-1-((3-chlorophenyl)sulfonyl)piperidine-4-carbonitrile
  参考文献：
  名称：

  Development of a Novel Human Parathyroid Hormone Receptor 1 (hPTHR1) Agonist (CH5447240), a Potent and Orally Available Small Molecule for Treatment of Hypoparathyroidism

  摘要：

  During the course of derivatization of HTS hit 4a, we have identified a novel small-molecule hPTHRl agonist, l-(3,5-dimethyl-4-(2-((2-((lR,4R)-4-methylcyclohexyl)-4-oxo-l,3,8-triazaspiro[4.5]dec-l-en-8-yl)sulfonyl)ethyl)-phenyl)-l-methylurea (CH5447240, 141). Compound 141 exhibited a potent in vitro hPTHRl agonist effect with EC20 of 3.0 mu M and EC50 of 12 mu M and showed excellent physicochemical properties, such as high solubility in fasted state simulated intestinal fluid and good metabolic stability in human liver microsomes. Importantly, 141 showed 55% oral bioavailability and a significantly elevated serum calcium level in hypocalcemic model rats.

  DOI：

  10.1021/acs.jmedchem.8b00182

文献信息

• Spiroimidazolone derivative
  申请人：Esaki Toru

  公开号：US09169254B2

  公开（公告）日：2015-10-27

  The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R1, R2, R33, R34, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

  本发明涉及一种由以下式(1)表示的化合物：其中W、X、Y、R1、R2、R33、R34、m和n如权利要求中所定义，或其药学上可接受的盐。
• SPIROIMIDAZOLONE DERIVATIVE
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：EP2433940B9

  公开（公告）日：2015-10-28
• US9169254B2
  申请人：——

  公开号：US9169254B2

  公开（公告）日：2015-10-27
• US9487517B2
  申请人：——

  公开号：US9487517B2

  公开（公告）日：2016-11-08